Fast, efficient and super sensitive fluorescent based assay kit for screening of PPARy ligands

January 2016  |  Press Releases

Fast, efficient and super sensitive fluorescent based assay kit for screening of PPARy ligands


MILPITAS, Calif. - Jan. 7, 2016 - PRLog -- BioVision, Inc. proudly announces the launch of the first fluorometric PPARγ Ligand Screening/Characterization Assay Kit. The assay can be HTP adaptable and does not require special equipment. The biochemical assay shows high signal-to noise ratio, and is a rapid assay with preincubation time between the screened ligand and PPARγ of 5 minutes. The assay utilizes the ability of potential PPARγ-binding ligands to displace a fluorescent probe, which has a strong affinity for PPARγ Ligand Binding Domain, resulting in loss of fluorescence of the probe. The relative drop in the fluorescence, as a result of competitive binding of PPARγ ligand, can be correlated to the affinity (and hence IC50) of the PPARγ candidate ligand. BioVision’s PPARγ Ligand Screening Assay Kit is easy to use, faster and more convenient as compared to Fluorescence Polarization and TR-FRET-based screening methods. The assay kit can be used to identify and characterize PPARγ-specific ligands for therapeutic applications.

Key Features:

1.Easy to use sensitive and quantitative

2.High-Throughput compatible

3.Kit includes a PPARγ ligand control and a stable, recombinant human PPARγ


1. Screening of drugs and novel ligands for interaction with recombinant human PPARγ ligand binding domain

2. Development of structure-activity relationship (SAR) models to predict       PPARγ/Ligand interaction.

3. Prediction of adverse protein/ligand interaction.

A variety of PPARγ-specific ligands (GW 1929, Rosiglitazone, Ciglitazone and Pioglitazone) and a PPARα-specific ligand (WY 14643) were tested using PPARγ Ligand Screening Assay Kit. Assays were performed following the kit protocol.

Peroxisome Proliferator receptors (PPARs) play important role in the regulation of adipogenesis, cellular differentiation, atherosclerosis, cancer and insulin sensitization. They are known to exist in two protein isoforms (Υ1 and Υ2), expressed mainly in adipose tissue, but have been traced in retinal and colonic areas as well. The increasing use of synthetic ligands in understanding PPARy receptor helps in identifying new drug candidates. Pioglitazone and Rosiglitazone are potent agonists belonging to the Thiazolidinedione (TZD) class of compounds. Fatty acids, arachidonic acid metabolites are also considered ligands of PPARY receptor. BioVision catalog number for this product is K437-100, visit for more details.

About BioVision:

BioVision, Inc. is a privately held Life Science company headquartered in the beautiful San Francisco Bay area. BioVision develops and offers a wide variety of products including assay kits, antibodies, recombinant proteins & enzymes, and other innovative research tools for studying Apoptosis, Metabolism, Cell Proliferation, Cellular Stress, Cell Damage and Repair, Diabetes, Obesity and Metabolic Syndrome, Stem Cell Biology, Gene Regulation, Signal Transduction, and more.